Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders

Trends Biotechnol. 2018 Mar;36(3):290-303. doi: 10.1016/j.tibtech.2017.11.004. Epub 2017 Dec 11.

Abstract

Neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases are highly prevalent and immensely destructive to the health and well-being of individuals and their families across the globe. Neurodegenerative diseases are characterized by the gradual loss of neural tissue in the central nervous system. Clearly, early diagnosis of the onset of neurodegeneration is vital and beneficial. Current diagnostic methods rely heavily on symptoms or autopsy results, thus overlooking early diagnosis, the only opportunity for amelioration. However, appropriately selected and used biomarker diagnostics provide a solution. This article reviews the development and application of biomarker-related diagnostics for neurodegenerative disease with specific recommendations for point-of-care (POC) methodology. These advantageous approaches may offer a solution to existing obstacles and limitations to neurodegenerative disease treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / blood
  • Alzheimer Disease / diagnosis*
  • Biomarkers / blood
  • Diagnostic Equipment
  • Early Diagnosis
  • Humans
  • Huntington Disease / blood
  • Huntington Disease / diagnosis*
  • Parkinson Disease / blood
  • Parkinson Disease / diagnosis*
  • Point-of-Care Systems*
  • Sensitivity and Specificity

Substances

  • Biomarkers